Results 11 to 20 of about 25,935 (265)

GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma [PDF]

Clinical Cancer Research
Abstract Purpose: Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects ...
Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella, Simona Caruso, Simona Manni, Alessio Ottaviani, Marika Guercio, Francesca Del Bufalo, Maria Cecilia Quadraccia, Domenico Orlando, Stefano Di Cecca, Matilde Sinibaldi, Mariasole Aurigemma, Laura Iaffaldano, Andrea Sarcinelli, Maria Luisa D'Amore, Manuela Ceccarelli, Francesca Nazio, Veronica Marabitti, Ezio Giorda, Marco Pezzullo, Cristiano De Stefanis, Andrea Carai, Sabrina Rossi, Rita Alaggio, Giada Del Baldo, Marco Becilli, Angela Mastronuzzi, Biagio De Angelis, Franco Locatelli   +30 more
openalex   +6 more sources

GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer [PDF]

Frontiers in Oncology, 2023
BackgroundOvarian cancer (OC) is the deadliest gynecological cancer, often diagnosed at advanced stages. A fast and accurate diagnostic method for early-stage OC is needed.
Alba Galan, Arturo Papaluca, Arturo Papaluca, Ali Nejatie, Ali Nejatie, Emad Matanes, Emad Matanes, Fouad Brahimi, Wenyong Tong, Wenyong Tong, Ibrahim Yaseen Hachim, Amber Yasmeen, Euridice Carmona, Kathleen Oros Klein, Kathleen Oros Klein, Sonja Billes, Ahmed E. Dawod, Prasad Gawande, Anna Milik Jeter, Anne-Marie Mes-Masson, Anne-Marie Mes-Masson, Celia M. T. Greenwood, Celia M. T. Greenwood, Walter H. Gotlieb, Walter H. Gotlieb, H. Uri Saragovi, H. Uri Saragovi, H. Uri Saragovi   +27 more
doaj   +2 more sources

GD2 expression in breast cancer

Oncotarget, 2017
Breast cancer (BC) is a heterogeneous disease, including different subtypes having diverse incidence, drug-sensitivity and survival rates. In particular, claudin-low and basal-like BC have mesenchymal features with a dismal prognosis. Disialoganglioside GD2 is a typical neuroectodermal antigen expressed in a variety of cancers.
Giulia Orsi, Monica Barbolini, Guido Ficarra, Giovanni Tazzioli, Paola Manni, Tiziana Petrachi, Ilenia Mastrolia, Enrico Orvieto, Carlotta Spano, Malvina Prapa, Shaniko Kaleci, Roberto D’Amico, Valentina Guarneri, Maria Vittoria Dieci, Stefano Cascinu, Pierfranco Conté, Federico Piacentini, Massimo Dominici   +17 more
openalex   +5 more sources

Functional activity of anti-GD2 CAR-T cells with different antigen-recognition module

Медицинская иммунология
Neuroblastoma (NB) is the most common extracranial solid tumor in children comprising, 8 to 10% of all pediatric tumors, with incidence of about 1-1.3 cases per 100,000 children under 15 years of age.
D. V. Lutskovich, M. A. Keraz, H. V. Klych, E. S. Lutskovich, A. N. Meleshko   +4 more
doaj   +3 more sources

Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy [PDF]

Journal of Immunology Research, 2017
Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on ...
Julien Fleurence, Sophie Fougeray, Meriem Bahri, Denis Cochonneau, Béatrice Clémenceau, François Paris, Andras Heczey, Stéphane Birklé   +7 more
doaj   +4 more sources

Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells [PDF]

Journal for ImmunoTherapy of Cancer, 2021
Background Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with no effective standard therapy. Breast cancer stem-like cells (BCSCs) in primary TNBCs are reported to be responsible for metastatic spread of the disease ...
Debasish Tripathy, Khoa Nguyen, Stanley Ly, Vivek Anand, Fouad El-Dana, Yiming Cai, Shirong Cai, Helen Piwnica-Worms, Aysegul A Sahin, Michael Andreeff, Venkata Lokesh Battula   +10 more
doaj   +3 more sources

Anti-GD2 Monoclonal Antibody hu14.18K322A [PDF]

, 2020
National Cancer Institute
openalex   +2 more sources

Anti-GD2 Antibody Therapy for GD2-Expressing Tumors [PDF]

Current Cancer Drug Targets, 2010
In the development of novel immune therapies for high-risk cancers, one goal is to find tumor targets that are not widely shared by normal cells. One such target is the surface disialoganglioside GD2. This antigen is expressed on the surface of a variety of tumors for which no curative therapies exist for patients with advanced disease.
Fariba, Navid, Victor M, Santana, Raymond C, Barfield   +2 more
openaire   +2 more sources

Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA [PDF]

Journal of Immunological Methods, 2011
Two assay methods for quantification of the disialoganglioside (GD2)-specific binding activities of anti-GD2 monoclonal antibodies and antibody immunofusion proteins, such as ch14.18 and hu14.18-IL2, were developed. The methods differed in the use of either microtiter plates coated with purified GD2 or plates seeded with GD2-expressing cell lines to ...
Gopalan, Soman, Xiaoyi, Yang, Hengguang, Jiang, Steve, Giardina, Gautam, Mitra   +4 more
openaire   +2 more sources

IMMU-55. GD2 IS A MACROPHAGE CHECKPOINT MOLECULE AND COMBINED GD2/CD47 BLOCKADE RESULTS IN SYNERGISTIC EFFECTS AGAINST GD2 POSITIVE MALIGNANCIES [PDF]

Neuro-Oncology, 2020
Abstract GD2 is a disialoganglioside expressed on a variety of tumors including DIPG, neuroblastoma and osteosarcoma. Anti-GD2 antibodies have demonstrated some success in neuroblastoma and they have either not proven to be effective or have not been evaluated in other GD2 positive malignancies. CD47 is the dominant “Don’t Eat Me” signal
Johanna Theruvath, Christopher Mount, Michelle Monje, Crystal Mackall, Robbie Majzner   +4 more
openaire   +1 more source